Overview
As the treatment landscape for patients with metastatic castration-resistant prostate cancer (mCRPC) continues to evolve, this research used the US nationwide Flatiron Health EHR-derived database to better understand treatment patterns in a cohort of >6,300 patients.
The researchers found 78% of patients received at least 1 line of therapy in the mCRPC setting, with the most common first-line (1L) and 2L therapies being androgen receptor pathway inhibitors (ARPI) based therapies or chemotherapy. ARPI use before mCRPC diagnosis has increased in both the mHSPC and nmCRPC settings in recent years (2018 - 2022), although only one third or patients received ARPI before mCRPC diagnosis, overall.. Despite not being recommended by current guidelines, consecutive use of ARPI in the mCRPC setting was common in patients regardless of if they received ARPI before the mCRPC setting or not.
Why this matters
Using real-world data, researchers were able to identify treatment patterns commonly used in community practice for the pre-mCRPC and mCRPC settings , improving our understanding of how novel treatments are being used, identifying additional research opportunities, and enabling informed treatment decisions by providing information in an evolving treatment landscape.